Annual report
7459.TEDINET S100YI1C
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.82T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥3.67T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.36T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥53.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥55.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥75.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥65.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥65.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥81.8bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥76.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥42.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥38.8bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥53.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥51.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.92T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.82T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.80T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.71T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.71T | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.13T | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.07T | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥795.4bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥736.6bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥688.1bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥649.1bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥289.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥261.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥286.5bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥259.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥260.4bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥46.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥60.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥9.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥39.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥29.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥43.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥206.67 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.82 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥179.12 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,186.01 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,979.39 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,858.57 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,673.62 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,525.72 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.9% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,024 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 13,061 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 13,075 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 12,795 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 12,801 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥31.2bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥30.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥30.3bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥33.0bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥26.6bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Operating income | ¥17.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥19.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥23.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.9bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.2bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥23.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥16.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥20.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥371.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥368.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥368.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥355.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥373.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥27.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥23.7bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥343.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥345.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥345.7bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥333.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥321.0bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥49.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥35.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥77.75 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.58 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.55 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.07 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.99 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥98.81 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.93 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥66 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥62 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,677.78 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,659.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,646.21 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,588.95 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,528.64 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 92.5% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 215,975,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 219,226,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 221,291,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 225,463,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 186 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 185 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 183 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 173 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 173 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥12m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥110m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥51.8bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | ¥134m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥486m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | employees | at 2026-03-31 | 796 pure |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥117.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥117.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2026-03-31 | ¥80.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.3bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥6.3bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | employees | at 2026-03-31 | 2363 pure |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.24T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.24T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥283m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥529.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥26.4bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥8.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | employees | at 2026-03-31 | 9667 pure |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.47T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.46T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.6bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥1.26T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥24.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥3.82T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥3.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.87T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥53.0bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥148m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥41m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥38.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥50m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥702m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2025-03-31 | ¥83.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥345m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥503.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥28.0bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥8.6bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥1.20T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.68T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥3.67T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.79T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥55.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,157
| Item | Context | Value | Unit |
|---|---|---|---|
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 0.603 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.623 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.849 | |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 173 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 173 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 183 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 185 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 186 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 12 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 12 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 12 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 12 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 12 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.969 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.892 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.163 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.199 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.514 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior5YearDuration_ConsolidatedAccountingGroupMember | 82532 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 67869 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 20 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 10.3 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 74.7 | |
| Research and development expenses research and development activities | CurrentYearDuration | 1512000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 683000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 21000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 808000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 9870000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 215975042 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 215975042 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 215975042 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 215975042 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 29 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 25 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 178 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 353 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 8 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 9013 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 9606 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 475696 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 53213 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |